Premium
Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial
Author(s) -
Tsounapi Panagiota,
Honda Masashi,
Dimitriadis Fotios,
Koukos Sotirios,
Hikita Katsuya,
Zachariou Athanasios,
Sofikitis Nikolaos,
Takenaka Atsushi
Publication year - 2018
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/and.13071
Subject(s) - sperm , sperm motility , capacitation , artificial insemination , andrology , hyperactivation , biology , semen , medicine , pregnancy , genetics , cancer research
Abstract The main objective of this study was to evaluate the effects of a micronutrient supplementation ( MS ) combined with avanafil on sperm function. Oligoasthenospermic men ( n = 217) were treated daily for 90 days with either an MS (45 men, Group A), l ‐carnitine (44 men, Group B), MS plus avanafil (43 men, Group C) or avanafil (43 men, Group D); another group of 42 men with oligoasthenospermia (Group E) received no treatment. Sperm parameters were evaluated before and after the end of treatment in each Group A, B, C and D respectively. The same sperm parameters were measured in each participant of Group E before and at the 90‐day experimental period. Within Groups A, C or D, the total percentage of motile spermatozoa, the hypoosmotic swelling test ( HOST ) result and the percentage of hyperactivated spermatozoa after incubation under conditions known to induce sperm capacitation were significantly greater after MS or MS plus avanafil treatment, or avanafil treatment than before the respective treatment. We suggest that MS or MS plus avanafil combined administration or avanafil alone improves sperm membrane permeability with an overall result improvement in sperm motility, outcome of HOST and increase in the percentage of hyperactivated spermatozoa.